Semaglutide for Prediabetes: What the Evidence Shows

If you have just been told you have prediabetes, you may be wondering whether a drug like semaglutide — sold as Ozempic or Wegovy — could stop it from becoming type 2 diabetes. It is a fair question, and the honest answer has two parts. The evidence that semaglutide improves blood sugar and pushes many people back toward normal is genuinely strong. But "prediabetes" is not, by itself, an FDA-approved reason to prescribe it. That distinction matters, so let's walk through it carefully.

Prediabetes means your blood sugar is higher than normal but not yet in the diabetes range — typically an HbA1c of 5.7–6.4%. It is a warning light, not a diagnosis of diabetes, and the central fact about it is that it is often reversible. That is exactly why the framing around semaglutide here is about risk reduction, not a cure for a labeled disease.

What the trials actually show

The most relevant evidence comes indirectly, from the obesity trials rather than a dedicated "prediabetes" study. In the STEP 1 trial — the 68-week study behind Wegovy — a large share of participants had prediabetes at the start, because elevated blood sugar travels with excess weight. By the end, once-weekly semaglutide 2.4 mg produced about 14.9% mean weight loss versus placebo, and a meaningfully larger proportion of people on semaglutide reverted from prediabetes to normal blood-sugar status than those on placebo¹.

That is an important and encouraging signal. But read it precisely: this was a weight-loss trial in adults with overweight or obesity, and the glycemic improvement rode along with the weight loss. STEP 1 was not designed as a prediabetes-treatment study, and "reverting to normoglycemia in a trial" is not the same as a regulatory approval to treat prediabetes.

Why the benefit is mostly weight-driven

The mechanism is the same one that makes semaglutide a weight and diabetes drug: it is a GLP-1 receptor agonist that reduces appetite, slows stomach emptying, and improves how your body handles glucose. For prediabetes specifically, the dominant lever is weight. Losing a meaningful amount of body weight reduces insulin resistance, lowers fasting glucose, and cuts the risk of progressing to type 2 diabetes. Semaglutide produces that weight loss reliably — and the blood-sugar improvement largely follows from it.

This is why it is fair to say semaglutide can lower someone's progression risk: not through a special prediabetes mechanism, but by doing what it already does well. For a fuller picture of how the drug works and what the broader trials show, see our semaglutide evidence guide.

The honest catch: this is off-label for prediabetes

Here is the part that gets glossed over. Semaglutide is not FDA-approved for prediabetes. Its approvals are for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Many people with prediabetes also meet the weight criteria for Wegovy, so they may qualify on that basis — but prescribing it for prediabetes as a standalone reason is off-label, aimed at weight and risk reduction rather than a labeled indication.

Off-label prescribing is legal and common when a clinician judges it appropriate, but it has real consequences: insurance is far less likely to cover a drug for an unapproved use, and you take on the cost and the risk-benefit conversation more directly. This is a decision to make with a clinician, not a reason to self-source.

Lifestyle change comes first — and it works

For prediabetes, the first-line, best-evidenced intervention is not a drug at all. Structured lifestyle change — sustained dietary change, increased activity, and modest weight loss — has long been shown to substantially cut progression to type 2 diabetes, and major prevention programs are built around it. Metformin, a cheap generic pill, is also commonly used for prediabetes risk reduction and has decades of safety data; we compare it with semaglutide directly in metformin vs semaglutide, and they are sometimes used together — see semaglutide and metformin.

The honest sequence for most people is: lifestyle change first; metformin as an inexpensive, well-established add-on; and a powerful GLP-1 like semaglutide considered when weight is a major driver and other measures aren't enough — ideally where the person also qualifies on weight grounds.

Cost, access, and the regain problem

Two practical realities should shape expectations. First, cost and access: semaglutide is expensive, and for an off-label prediabetes use, insurance coverage is unlikely. Lifestyle change and metformin are dramatically cheaper, which matters for something you may need to sustain for years.

Second, and most important, the benefit depends on staying on it. In the STEP 1 trial extension, when people stopped semaglutide they regained roughly two-thirds of the lost weight over the following year, and the metabolic improvements reversed alongside it. For prediabetes that is a pointed warning: the glycemic benefit is largely a function of the weight loss, so if the weight comes back, so does much of the risk. This is not a short course that "fixes" prediabetes — it is an ongoing therapy whose benefits fade when it stops. We cover the duration question in how long to stay on semaglutide.

The bottom line

Semaglutide clearly can help people with prediabetes: in the obesity trials, a large share of participants with prediabetes reverted to normal blood sugar, driven by substantial weight loss¹. But it is not FDA-approved for prediabetes — that use is off-label and aimed at weight and risk reduction. Lifestyle change remains first-line, metformin is a cheaper established option, cost and coverage are real hurdles, and the benefit largely reverses if you stop. If you're weighing this, do it with a clinician, and use our calculators and tools to think through the numbers.